Solid Biosciences Added to the Nasdaq Biotechnology Index
Solid Biosciences (Nasdaq: SLDB), a life sciences company focused on precision genetic medicines for neuromuscular and cardiac diseases, has been added to the Nasdaq Biotechnology Index® (NBI) effective December 23, 2024. The NBI tracks performance of biotechnology and pharmaceutical securities listed on Nasdaq, using a modified capitalization-weighted methodology. Companies must meet specific eligibility criteria including minimum market capitalization, daily trading volume, and public company seasoning requirements. Index constituents are selected annually in December.
Solid Biosciences (Nasdaq: SLDB), un'azienda delle scienze della vita focalizzata su medicine genetiche di precisione per malattie neuromuscolari e cardiache, è stata aggiunta all'indice Nasdaq Biotechnology® (NBI) con effetto dal 23 dicembre 2024. L'NBI monitora le performance delle titoli biotecnologici e farmaceutici quotati su Nasdaq, utilizzando una metodologia di capitalizzazione ponderata modificata. Le aziende devono soddisfare specifici criteri di idoneità, inclusa la capitalizzazione di mercato minima, il volume di scambi giornaliero e i requisiti di esperienza come società pubblica. I componenti dell'indice sono selezionati annualmente a dicembre.
Solid Biosciences (Nasdaq: SLDB), una empresa de ciencias de la vida centrada en medicamentos genéticos de precisión para enfermedades neuromusculares y cardíacas, ha sido agregada al índice Nasdaq Biotechnology® (NBI) a partir del 23 de diciembre de 2024. El NBI rastrea el rendimiento de valores biotecnológicos y farmacéuticos listados en Nasdaq, utilizando una metodología de capitalización ponderada modificada. Las empresas deben cumplir criterios específicos de elegibilidad, incluidos una capitalización de mercado mínima, volumen diario de negociación y requisitos de experiencia como empresa pública. Los componentes del índice se seleccionan anualmente en diciembre.
솔리드 바이오사이언스 (Nasdaq: SLDB)은 신경근육 및 심장 질병을 위한 정밀 유전 의약품에 주력하는 생명 과학 회사로, 2024년 12월 23일부로 나스닥 생명공학 지수(NBI)에 추가되었습니다. NBI는 나스닥에 상장된 생명공학 및 제약 증권의 성과를 추적하며, 수정된 시가 총액 가중 방법론을 사용합니다. 기업은 최소 시가 총액, 일일 거래량, 공개 기업 경력 요건을 포함한 특정 적격성 기준을 충족해야 합니다. 지수 구성 요소는 매년 12월에 선택됩니다.
Solid Biosciences (Nasdaq: SLDB), une entreprise de sciences de la vie axée sur des médicaments génétiques de précision pour les maladies neuromusculaires et cardiaques, a été ajoutée à l'indice Nasdaq Biotechnology® (NBI) en date du 23 décembre 2024. Le NBI suit la performance des valeurs biotechnologiques et pharmaceutiques listées sur le Nasdaq, à l'aide d'une méthodologie de capitalisation boursière modifiée. Les entreprises doivent répondre à des critères d'éligibilité spécifiques incluant une capitalisation boursière minimale, un volume de négociation quotidien, et des exigences de longévité en tant qu'entreprise publique. Les composants de l'indice sont sélectionnés chaque année en décembre.
Solid Biosciences (Nasdaq: SLDB), ein Unternehmen im Bereich der Lebenswissenschaften, das sich auf präzise genetische Arzneimittel für muskuloskelettale und kardiovaskuläre Erkrankungen konzentriert, wurde zum Nasdaq Biotechnology Index® (NBI) ab dem 23. Dezember 2024 hinzugefügt. Der NBI verfolgt die Performance von Biotechnologie- und Pharmawerten, die an der Nasdaq gelistet sind, unter Verwendung einer modifizierten kapitalisierungsgewichteten Methodik. Unternehmen müssen spezifische Zulassungskriterien erfüllen, einschließlich einer minimalen Marktkapitalisierung, eines täglichen Handelsvolumens und der Anforderungen an die öffentliche Unternehmensreife. Die Indexbestandteile werden jährlich im Dezember ausgewählt.
- Addition to Nasdaq Biotechnology Index increases visibility and potential institutional investment exposure
- Company meets minimum market cap and trading volume requirements for index inclusion
- None.
CHARLESTOWN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it was added to the Nasdaq Biotechnology Index® (Nasdaq: NBI) effective prior to the market open on Monday, December 23, 2024.
The Nasdaq Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NBI is calculated under a modified capitalization-weighted methodology. Companies in the NBI must meet eligibility requirements, including minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria. Nasdaq selects constituents once annually in December.
For more information about the Nasdaq Biotechnology Index, please visit https://indexes.nasdaqomx.com/Index/Overview/NBI.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
When was Solid Biosciences (SLDB) added to the Nasdaq Biotechnology Index?
What are the requirements for joining the Nasdaq Biotechnology Index that SLDB met?
How often does the Nasdaq Biotechnology Index update its constituents?
What type of weighting methodology does the NBI use for stocks like SLDB?
